Asensus Surgical (TRXDW) 10-Q 5 Aug 20 2020 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Jul. 31, 2020
Document Information [Line Items]
Entity Central Index Key	0000876378
Entity Registrant Name	TRANSENTERIX, INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2020
Document Transition Report	false
Entity File Number	0-19437
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-2962080
Entity Address, Address Line One	635 Davis Drive, Suite 300
Entity Address, City or Town	Morrisville
Entity Address, State or Province	NC
Entity Address, Postal Zip Code	27560
City Area Code	919
Local Phone Number	765-8400
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Title of 12(b) Security	Common Stock $0.001 par value per share
Trading Symbol	TRXC
Security Exchange Name	NYSEAMER
Entity Common Stock, Shares Outstanding		99,876,465

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenue:
Revenue	$ 655	$ 3,639	$ 1,255	$ 5,820
Cost of revenue:
Cost of revenue	1,413	3,936	3,151	6,403
Gross loss	(758)	(297)	(1,896)	(583)
Operating Expenses:
Research and development	4,257	6,295	8,191	11,950
Sales and marketing	2,901	7,868	7,154	15,542
General and administrative	3,619	4,489	6,968	9,049
Amortization of intangible assets	2,619	2,585	5,183	5,196
Change in fair value of contingent consideration	212	960	1,268	1,958
Restructuring and other charges	0	0	858	0
Acquisition related costs	0	0	0	45
Loss from sale of SurgiBot assets, net	0	0	0	97
Total Operating Expenses	13,608	22,197	29,622	43,837
Operating Loss	(14,366)	(22,494)	(31,518)	(44,420)
Other Income (Expense):
Change in fair value of warrant liabilities	(114)	2,528	(269)	2,422
Interest income	4	178	31	496
Interest expense	0	(1,061)	0	(2,177)
Other expense	(55)	(191)	(70)	(496)
Total Other Income (Expense), net	(165)	1,454	(308)	245
Loss before income taxes	(14,531)	(21,040)	(31,826)	(44,175)
Income tax benefit	691	869	1,388	1,479
Net loss	(13,840)	(20,171)	(30,438)	(42,696)
Deemed dividend related to beneficial conversion feature of preferred stock	0	0	(412)	0
Deemed dividend related to conversion of preferred stock into common stock	(299)	0	(299)	0
Net loss attributable to common stockholders	(14,139)	(20,171)	(31,149)	(42,696)
Comprehensive loss:
Net loss	(13,840)	(20,171)	(30,438)	(42,696)
Foreign currency translation gain (loss)	962	1,240	90	(709)
Comprehensive loss	$ (12,878)	$ (18,931)	$ (30,348)	$ (43,405)
Net loss per common share attributable to common stockholders - basic (in dollars per share)	$ (0.27)	$ (1.21)	$ (0.77)	$ (2.56)
Net loss per common share attributable to common stockholders - diluted (in dollars per share)	$ (0.27)	$ (1.35)	$ (0.77)	$ (2.68)
Weighted average number of shares used in computing net loss per common share - basic (in shares)	52,351	16,729	40,628	16,703
Weighted average number of shares used in computing net loss per common share - diluted (in shares)	52,351	16,814	40,628	16,814
Product [Member]
Revenue:
Revenue	$ 315	$ 3,342	$ 557	$ 5,171
Cost of revenue:
Cost of revenue	720	2,956	1,633	4,229
Service [Member]
Revenue:
Revenue	340	297	698	649
Cost of revenue:
Cost of revenue	$ 693	$ 980	$ 1,518	$ 2,174

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current Assets:
Cash and cash equivalents	$ 15,603	$ 9,598
Accounts receivable, net	971	620
Inventories	10,857	10,653
Other current assets	6,881	7,084
Total Current Assets	34,312	27,955
Restricted cash	627	969
Inventories, net of current portion	6,334	7,594
Property and equipment, net	6,963	4,706
Intangible Assets	25,802	28,596
Net deferred tax assets	40	0
Other long term assets	1,896	2,489
Total Assets	75,974	74,779
Current Liabilities:
Accounts payable	2,347	3,579
Accrued expenses	6,840	8,553
Deferred revenue - current portion	868	818
Contingent consideration - current portion	0	73
Total Current Liabilities	10,055	13,023
Long Term Liabilities:
Deferred revenue - less current portion	0	27
Contingent consideration - less current portion	2,278	1,011
Notes payable, net of issuance costs	2,815	0
Warrant liabilities	187	2,388
Net deferred tax liabilities	0	1,392
Other long term liabilities	1,082	1,403
Total Liabilities	16,417	19,244
Commitments and Contingencies (Note 13)
Stockholders' Equity:
Common stock $0.001 par value, 750,000,000 shares authorized at June 30, 2020 and December 31, 2019; 56,902,140 and 20,691,301 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively	57	21
Preferred stock, $0.01 par value, 25,000,000 shares authorized, including 7,937,057 and 0 shares of Series A Convertible Preferred Stock at June 30, 2020 and December 31, 2019, and 0 shares issued and outstanding at June 30, 2020 and December 31, 2019	0	0
Additional paid-in capital	754,818	720,484
Accumulated deficit	(694,038)	(663,600)
Accumulated other comprehensive loss	(1,280)	(1,370)
Total Stockholders' Equity	59,557	55,535
Total Liabilities and Stockholders' Equity	75,974	74,779
Intellectual Property [Member]
Current Assets:
Intangible Assets	25,802	28,596
In Process Research and Development [Member]
Current Assets:
Intangible Assets	$ 0	$ 2,470

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	750,000,000	750,000,000
Common stock, shares issued (in shares)	56,902,140	20,691,301
Common stock, shares outstanding (in shares)	56,902,140	20,691,301
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	25,000,000	25,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Convertible Preferred Stock [Member]
Preferred stock, shares authorized (in shares)	7,937,057	0

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Public Offering [Member]Common Stock [Member]	Public Offering [Member]Preferred Stock [Member]	Public Offering [Member]Treasury Stock [Member]	Public Offering [Member]Additional Paid-in Capital [Member]	Public Offering [Member]Retained Earnings [Member]	Public Offering [Member]AOCI Attributable to Parent [Member]	Public Offering [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Common Stock [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Preferred Stock [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Treasury Stock [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Additional Paid-in Capital [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Retained Earnings [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]AOCI Attributable to Parent [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]	Common Stock [Member]	Preferred Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2018															16,642	0	0
Balance at Dec. 31, 2018								$ 0	$ 0	$ 0	$ (7)	$ 7	$ 0	$ 0	$ 17	$ 0	$ 0	$ 676,572	$ (509,406)	$ 1,338	$ 168,521
Stock-based compensation															$ 0	$ 0	$ 0	2,981	0	0	2,981
Award of restricted stock units (in shares)															47	0	0
Award of restricted stock units															$ 0	$ 0	$ 0	1	0	0	1
Return of common stock to pay withholding taxes on restricted stock (in shares)															0	0	15
Return of common stock to pay withholding taxes on restricted stock															$ 0	$ 0	$ 0	(499)	0	0	(499)
Cancellation of treasury stock (in shares)															0	0	(15)
Cancellation of treasury stock															$ 0	$ 0	$ 0	0	0	0	0
Other comprehensive income (loss)															0	0	0	0	0	(1,949)	(1,949)
Net loss															$ 0	$ 0	$ 0	0	(22,525)	0	(22,525)
Balance (in shares) at Mar. 31, 2019															16,701	0	0
Balance at Mar. 31, 2019															$ 17	$ 0	$ 0	679,284	(531,924)	(611)	146,766
Balance (in shares) at Dec. 31, 2018															16,642	0	0
Balance at Dec. 31, 2018								0	0	0	(7)	7	0	0	$ 17	$ 0	$ 0	676,572	(509,406)	1,338	168,521
Net loss																					(42,696)
Balance (in shares) at Jun. 30, 2019															16,740	0	0
Balance at Jun. 30, 2019															$ 17	$ 0	$ 0	682,936	(552,095)	629	131,487
Balance (in shares) at Dec. 31, 2018															16,642	0	0
Balance at Dec. 31, 2018								$ 0	$ 0	$ 0	$ (7)	$ 7	$ 0	$ 0	$ 17	$ 0	$ 0	676,572	(509,406)	1,338	168,521
Exercise of stock options and warrants (in shares)															12	0	0
Exercise of stock options and warrants															$ 0	$ 0	$ 0	236	0	0	236
Balance (in shares) at Jun. 30, 2020															56,903	0	0
Balance at Jun. 30, 2020															$ 57	$ 0	$ 0	754,818	(694,038)	(1,280)	59,557
Balance (in shares) at Mar. 31, 2019															16,701	0	0
Balance at Mar. 31, 2019															$ 17	$ 0	$ 0	679,284	(531,924)	(611)	146,766
Stock-based compensation															$ 0	$ 0	$ 0	3,355	0	0	3,355
Award of restricted stock units (in shares)															14	0	0
Award of restricted stock units															$ 0	$ 0	$ 0	0	0	0	0
Other comprehensive income (loss)															0	0	0	0	0	1,240	1,240
Net loss															$ 0	$ 0	$ 0	0	(20,171)	0	(20,171)
Exercise of stock options and warrants (in shares)															25	0	0
Exercise of stock options and warrants															$ 0	$ 0	$ 0	297	0	0	297
Balance (in shares) at Jun. 30, 2019															16,740	0	0
Balance at Jun. 30, 2019															$ 17	$ 0	$ 0	682,936	(552,095)	629	131,487
Balance (in shares) at Dec. 31, 2019															20,691	0	0
Balance at Dec. 31, 2019															$ 21	$ 0	$ 0	720,484	(663,600)	(1,370)	55,535
Stock-based compensation															$ 0	$ 0	$ 0	1,923	0	0	1,923
Issuance of stock (in shares)	14,122	7,937	0												7,030	0	0
Issuance of stock	$ 14	$ 79	$ 0	$ 13,432	$ 0	$ 0	$ 13,525								$ 7	$ 0	$ 0	11,205	0	0	11,212
Conversion of preferred stock to common stock (in shares)															3,053	(3,053)	0
Conversion of preferred stock to common stock															$ 3	$ (30)	$ 0	27	0	0	0
Exchange of shares for Series B Warrants (in shares)															2,041	0	0
Exchange of shares for Series B Warrants															$ 2	$ 0	$ 0	2,468	0	0	2,470
Award of restricted stock units (in shares)															141	0	0
Award of restricted stock units															$ 0	$ 0	$ 0	0	0	0	0
Return of common stock to pay withholding taxes on restricted stock (in shares)															0	0	28
Return of common stock to pay withholding taxes on restricted stock															$ 0	$ 0	$ 0	(33)	0	0	(33)
Cancellation of treasury stock (in shares)															0	0	(28)
Cancellation of treasury stock															$ 0	$ 0	$ 0	0	0	0	0
Other comprehensive income (loss)															0	0	0	0	0	(872)	(872)
Net loss															$ 0	$ 0	$ 0	0	(16,598)	0	(16,598)
Balance (in shares) at Mar. 31, 2020															47,078	4,884	0
Balance at Mar. 31, 2020															$ 47	$ 49	$ 0	749,506	(680,198)	(2,242)	67,162
Balance (in shares) at Dec. 31, 2019															20,691	0	0
Balance at Dec. 31, 2019															$ 21	$ 0	$ 0	720,484	(663,600)	(1,370)	55,535
Conversion of preferred stock to common stock (in shares)															7,900	7,900
Net loss																					(30,438)
Exercise of stock options and warrants (in shares)															4,900
Balance (in shares) at Jun. 30, 2020															56,903	0	0
Balance at Jun. 30, 2020															$ 57	$ 0	$ 0	754,818	(694,038)	(1,280)	59,557
Balance (in shares) at Mar. 31, 2020															47,078	4,884	0
Balance at Mar. 31, 2020															$ 47	$ 49	$ 0	749,506	(680,198)	(2,242)	67,162
Stock-based compensation															$ 0	$ 0	$ 0	1,933	0	0	1,933
Conversion of preferred stock to common stock (in shares)															4,884	(4,884)	0
Conversion of preferred stock to common stock															$ 5	$ (49)	$ 0	44	0	0	0
Award of restricted stock units (in shares)															28	0	0
Award of restricted stock units															$ 0	$ 0	$ 0	0	0	0	0
Other comprehensive income (loss)															0	0	0	0	0	962	962
Net loss															$ 0	$ 0	$ 0	0	(13,840)	0	(13,840)
Exercise of warrants (in shares)															4,913	0	0
Exercise of warrants															$ 5	$ 0	$ 0	3,335	0	0	3,340
Balance (in shares) at Jun. 30, 2020															56,903	0	0
Balance at Jun. 30, 2020															$ 57	$ 0	$ 0	$ 754,818	$ (694,038)	$ (1,280)	$ 59,557

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Operating Activities:
Net loss	$ (13,840)	$ (16,598)	$ (20,171)	$ (22,525)	$ (30,438)	$ (42,696)
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:
Loss from sale of SurgiBot assets, net	0		0		0	97
Depreciation					1,162	1,126
Amortization of intangible assets	2,619		2,585		5,183	5,196
Amortization of debt discount and debt issuance costs					0	622
Amortization of short-term investment discount					0	(300)
Stock-based compensation					3,856	6,336
Interest expense on deferred consideration - MST acquisition					0	387
Deferred tax benefit					(1,388)	(1,479)
Write down of inventory	0		800		0	761
Change in fair value of warrant liabilities	114		(2,528)		269	(2,422)
Change in fair value of contingent consideration	212		960		1,268	1,958
Changes in operating assets and liabilities:
Accounts receivable					(350)	2,808
Interest receivable					0	(4)
Inventories					(2,332)	(10,301)
Other current and long term assets					827	(3,689)
Accounts payable					(1,221)	2,499
Accrued expenses					(1,736)	(1,454)
Deferred revenue					22	(862)
Other long term liabilities					(258)	1,879
Net cash and cash equivalents used in operating activities					(25,136)	(39,538)
Investing Activities:
Purchase of short-term investments					0	(12,883)
Proceeds from maturities of short-term investments					0	55,000
Purchase of property and equipment					(3)	(189)
Net cash and cash equivalents (used in) provided by investing activities					(3)	41,928
Financing Activities:
Proceeds from issuance of common stock, preferred stock and warrants under 2020 financing, net of issuance costs					13,525	0
Proceeds from issuance of common stock, net of issuance costs					11,212	0
Proceeds from notes payable, net of issuance costs					2,815	(30)
Taxes paid related to net share settlement of vesting of restricted stock units					(33)	(499)
Payment of contingent consideration					(74)	0
Proceeds from exercise of warrants					3,340	534
Net cash and cash equivalents provided by (used in) financing activities					30,785	5
Effect of exchange rate changes on cash and cash equivalents					17	(32)
Net increase in cash, cash equivalents and restricted cash					5,663	2,363
Cash, cash equivalents and restricted cash, beginning of period		$ 10,567		$ 21,651	10,567	21,651	$ 21,651
Cash, cash equivalents and restricted cash, end of period	$ 16,230		$ 24,014		16,230	24,014	$ 10,567
Supplemental Disclosure for Cash Flow Information:
Interest paid					0	1,528
Supplemental Schedule of Non-cash Investing and Financing Activities:
Transfer of inventories to property and equipment					3,403	415
Exchange of common stock for Series B Warrants					2,470	0
Transfer of in-process research and development to intellectual property					2,425	0
Conversion of preferred stock to common stock					$ 79	$ 0

Note 1 - Business Overview

Note 1 - Business Overview	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	1. Business Overview Overview TransEnterix, Inc. is a medical device company that is digitizing the interface between the surgeon and the patient in laparoscopy to increase control and reduce surgical variability in today’s value-based healthcare environment. It is focused on the market development for and commercialization of the Senhance® Surgical System, which digitizes laparoscopic minimally invasive surgery, or MIS. The Senhance Surgical System is the first 3 The Company believes that future outcomes of minimally invasive surgery will be enhanced through its combination of more advanced tools and robotic functionality, which are designed to empower surgeons with improved precision, ergonomics, dexterity and visualization; offer high patient satisfaction and enable a desirable post-operative recovery; and provide a cost-effective robotic system, compared to existing alternatives today, for a wide range of clinical applications and operative sites within the healthcare system. The Senhance System is commercially available in Europe, the United States, Japan and select other countries. • The Senhance System has a CE Mark in Europe for adult and pediatric laparoscopic abdominal and pelvic surgery, as well as limited thoracic surgeries excluding cardiac and vascular surgery. • In the United States, the Company has received 510 28 • In Japan, the Company has received regulatory approval and reimbursement for 98 Over the past 24 3 3 5 3 November 2019 first 2021. In January 2020, first fourth 2018. first March 13, 2020, The Company continues to make additional submissions for clearance or approval for enhancements to the Senhance System and related instruments and accessories, including additional filings and approvals sought in Japan. The Company is implementing its strategy to place Senhance Systems with customers pursuant to leasing arrangements and to work with its customers to increase utilization. As of July 31, 2020, six one July 2020. Risks and Uncertainties The Company is subject to risks similar to other similarly sized companies in the medical device industry. These risks include, without limitation: potential negative impacts on the Company's operations caused by the COVID- 19 In 2020, 1 not 2 3 not 10 19 During the fourth 2019, fourth 2019. first 2020, 2020. June 30, 2020 With respect to the COVID- 19 19 March 2020, June 2020. 2020 second 2020, not, 19 19

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Basis of Presentation The Company has prepared the accompanying unaudited interim condensed consolidated financial statements in accordance with the instructions to Form 10 not 10 10 not may 2019 10 not On December 11, 2019, one December 12, 2019. No Unless otherwise noted, all share and per share data referenced in the condensed consolidated financial statements and the notes thereto have been retroactively adjusted to reflect the Reverse Stock Split. As a result of the Reverse Stock Split, certain amounts in the condensed consolidated financial statements and the notes thereto may Liquidity and Going Concern The Company's condensed consolidated financial statements are prepared using U.S. GAAP applicable to a going concern, which contemplate the realization of assets and liquidation of liabilities in the normal course of business. The Company had an accumulated deficit of $694.0 million as of June 30, 2020 June 30, 2020. not The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. In order to continue as a going concern, the Company will need, among other things, additional capital resources. Traditionally, the Company has raised additional capital through equity offerings, including raising net proceeds of $13.5 million in the March 2020 10 July 2020 14 April 2020 may 8 may may one not not 19 At June 30, 2020, one not may Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include identifiable intangible assets and goodwill, contingent consideration, warrant liabilities, stock compensation expense, revenue recognition, accounts receivable reserves, excess and obsolete inventory reserves, inventory classification between current and non-current, and deferred tax asset valuation allowances. The COVID- 19 19 19 19 19 Principles of Consolidation and Foreign Currency Considerations The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its direct and indirect wholly owned subsidiaries, SafeStitch LLC, TransEnterix Surgical, Inc., TransEnterix International, Inc., TransEnterix Italia S.r.l., TransEnterix Europe S.à.R.L, TransEnterix Asia Pte. Ltd., TransEnterix Taiwan Ltd., TransEnterix Japan KK, TransEnterix Israel Ltd. and TransEnterix Netherlands B.V. All material inter-company accounts and transactions have been eliminated in consolidation. The functional currency of the Company’s operational foreign subsidiaries is predominantly the Euro. The assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at the average exchange rates prevailing during the period. The cumulative translation effect for a subsidiary using a functional currency other than the U.S. dollar is included in accumulated other comprehensive income or loss as a separate component of stockholders’ equity. The Company’s intercompany accounts are denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the remeasurement of intercompany receivables that the Company considers to be of a long-term investment nature are recorded as a cumulative translation adjustment in accumulated other comprehensive income or loss as a separate component of stockholders’ equity, while gains and losses resulting from the remeasurement of intercompany receivables from a foreign subsidiary for which the Company anticipates settlement in the foreseeable future are recorded in the condensed consolidated statements of operations and comprehensive loss. The net gains and losses included in net loss in the condensed consolidated statements of operations and comprehensive loss for the three six June 30, 2020 2019 not Concentrations and Credit Risk The Company’s principal financial instruments subject to potential concentration of credit risk are cash and cash equivalents, including amounts held in money market accounts. The Company places cash deposits with a federally insured financial institution. The Company maintains its cash at banks and financial institutions it considers to be of high credit quality; however, the Company’s domestic cash deposits may may not not not The Company’s accounts receivable are derived from sales to customers located throughout the world. The Company evaluates its customers’ financial condition and, generally, requires no no eight June 30, 2020. eight December 31, 2019. The Company had seven three June 30, 2020 five three June 30, 2019. nine six June 30, 2020 two six June 30, 2019. Cash and Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with original maturities of 90 Restricted cash at June 30, 2020 December 31, 2019 2018. Accounts Receivable Accounts receivable are recorded at net realizable value, which includes an allowance for estimated uncollectible accounts. The allowance for uncollectible accounts was determined on a customer specific basis based on deemed collectability. The allowance for doubtful accounts was $1.7 June 30, 2020 December 31, 2019. Inventories Inventories are stated at the lower of cost (determined on a first first not Any inventory on hand at the measurement date in excess of the Company's current requirements based on anticipated levels of sales is classified as long-term on the Company's condensed consolidated balance sheets. The Company’s classification of long-term inventory requires it to estimate the portion of on hand inventory that can be realized over the upcoming twelve Identifiable Intangible Assets and Goodwill Definite-Lived Intangible Assets - Intellectual Property Intellectual property consists of purchased patent rights and developed technology acquired as part of a business acquisition. Developed technology includes reclassified IPR&D assets related to (i) the Senhance System acquired in 2015 2017 2018 2020. The Company periodically evaluates intellectual property for impairment whenever events or changes in circumstances indicate that the carrying amount may not No six June 30, 2020 2019. Indefinite-Lived Intangible Assets – In-Process Research and Development In-process research and development (“IPR&D”) assets represent the fair value assigned to technologies that were acquired, which at the time of acquisition have not no The Company performed an impairment test of its IPR&D at the end of the third 2019 third 2019, December 31, 2019 no The Company reclassifies IPR&D assets to intellectual property when development is complete, which generally occurs upon regulatory approval and the Company is able to commercialize products. The completed IPR&D assets are then classified as definite-lived intangible assets (developed technology) and are amortized based on their estimated useful lives at that point in time. If development is terminated or abandoned, the Company may The Company did not three six June 30, 2020 2019. June 30, 2020, Goodwill Goodwill of $93.8 million was recorded in connection with a September 2013 3 The Company performs an annual impairment test of goodwill at December 31, one may not third 2019, Property and Equipment Property and equipment consists primarily of machinery, manufacturing equipment, demonstration equipment, computer equipment, furniture, and leasehold improvements, which are recorded at cost. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows: Machinery, manufacturing and demonstration equipment (in years) 3 - 5 Computer equipment (in years) 3 Furniture (in years) 5 Leasehold improvements Lesser of lease term or 3 to 10 years Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred. The Company reviews its property and equipment assets for possible impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not not three six June 30, 2020 2019. Contingent Consideration Contingent cash consideration arising from business combinations is recorded as a liability and is the estimate of the fair value of potential milestone payments related to those acquisitions. Contingent consideration is measured at fair value using a discounted cash flow model using significant unobservable inputs including the probability of achieving each of the potential milestones, future Euro-to-USD exchange rates, and an estimated discount rate associated with the risks of the expected cash flows attributable to the various milestones. Significant increases or decreases in any of the probabilities of success or changes in expected achievement of any of these milestones would result in a significantly higher or lower fair value of these milestones, respectively, and commensurate changes to the associated liability. The contingent consideration is revalued at each reporting period and changes in fair value are recognized in the condensed consolidated statements of operations and comprehensive loss. Warrant Liabilities The Company’s Series B Warrants (see Note 9 4 Revenue Recognition The Company’s revenue consists of product revenue resulting from the sale of Systems, System components, instruments and accessories, and service revenue. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company's revenues are measured based on consideration specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities. The Company’s System sale arrangements generally include a five first four The Company’s System sale arrangements generally contain multiple products and services. For these consolidated sale arrangements, the Company accounts for individual products and services as separate performance obligations if they are distinct, which is if a product or service is separately identifiable from other items in the consolidated package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company’s System sale arrangements may For arrangements that contain multiple performance obligations, revenue is allocated to each performance obligation based on its relative estimated standalone selling price. When available, standalone selling prices are based on observable prices at which the Company separately sells the products or services; however due to limited sales to date, standalone selling prices generally are not not The Company enters into lease arrangements with certain qualified customers. Revenue related to arrangements including lease elements are allocated to lease and non-lease elements based on their relative standalone selling prices. Lease elements generally include a Senhance System, while non-lease elements generally include service, instruments, and accessories. For some lease arrangements, the customers are provided with the right to purchase the leased System at some point during and/or at the end of the lease term. In some arrangements lease payments are based on the usage of the System. In determining whether a transaction should be classified as a sales-type or operating lease, the Company considers the following terms at lease commencement: ( 1 2 3 4 5 no June 30, 2020 The Company recognizes revenues as the performance obligations are satisfied by transferring control of the product or service to a customer. The Company generally recognizes revenue for the performance obligations as follows: ● System sales. For Systems and System components sold directly to end customers, revenue is recognized when the Company transfers control to the customer, which is generally at the point when acceptance occurs that indicates customer acknowledgment of delivery or installation, depending on the terms of the arrangement. For Systems sold through distributors, for which distributors are responsible for installation, revenue is recognized generally at the time of shipment. The Company’s System arrangements generally do not one not ● Lease arrangements. Revenue related to lease elements from operating lease arrangements is generally recognized on a straight-line basis over the lease term or based upon System usage and is presented as product revenue. ● Instruments and accessories. Revenue from sales of instruments and accessories is recognized when control is transferred to the customers, which generally occurs at the time of shipment, but also occurs at the time of delivery depending on the customer arrangement. ● Service. Service revenue is recognized ratably over the term of the service period as the customers benefit from the service throughout the service period. Revenue related to services performed on a time-and-materials basis is recognized when performed. The following table presents revenue disaggregated by type and geography (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 U.S. Systems $ 45 $ - $ 75 $ - Instruments and accessories 7 25 67 25 Services 103 127 171 260 Total U.S. revenue 155 152 313 285 Outside of U.S. ("OUS") Systems 117 2,782 127 4,065 Instruments and accessories 146 535 288 1,081 Services 237 170 527 389 Total OUS revenue 500 3,487 942 5,535 Total Systems 162 2,782 202 4,065 Instruments and accessories 153 560 355 1,106 Services 340 297 698 649 Total revenue $ 655 $ 3,639 $ 1,255 $ 5,820 The Company recognizes sales by geographic area based on the country in which the customer is based. Operating lease revenue is included in the above table and was approximately $0.1 million and $0 for the three June 30, 2020 2019, six June 30, 2020 2019, Transaction price allocated to remaining performance obligations relates to amounts allocated to products and services for which the revenue has not June 30, 2020 December 31, 2019, The Company invoices its customers based on the billing schedules in its sales arrangements. Contract assets for the periods presented primarily represent the difference between the revenue that was recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements. Contract assets are included in accounts receivable and totaled $0.1 million and $0.2 million as of June 30, 2020 December 31, 2019, not three June 30, 2020 2019, six June 30, 2020 2019, three six June 30, 2019 2017 first second 2019. June 30, 2020 one three In connection with assets recognized from the costs to obtain a contract with a customer, the Company determined that the sales incentive programs for its sales team do not not Cost of Revenue Cost of revenue consists of contract manufacturing, materials, labor and manufacturing overhead incurred internally to produce the products. Shipping and handling costs incurred by the Company are included in cost of revenue. During the three June 30, 2020 2019, six June 30, 2020 2019, Research and Development Costs Research and development expenses primarily consist of engineering, product development and regulatory expenses, incurred in the design, development, testing and enhancement of our products. Research and development costs are expensed as incurred. Stock-Based Compensation The Company follows ASC 718 not not not The fair value of restricted stock units is determined by the market price of the Company’s common stock on the date of grant. Compensation expense for stock-based compensation was approximately $1.9 million and $3.4 million for the three June 30, 2020 2019, six June 30, 2020 2019, On June 8, 2020, 2020 one The awards to the executive officers include the 2020 $1.00 twenty three The awards were all made under the Company’s Amended and Restated Incentive Compensation Plan. An aggregate of 2,061,289 shares of common stock underlie these awards if they fully vest. Income Taxes The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets or liabilities for the temporary differences between financial reporting and tax basis of the Company’s assets and liabilities, and for tax carryforwards at enacted statutory rates in effect for the years in which the asset or liability is expected to be realized. The effect on deferred taxes of a change in tax rates is recognized in income during the period that includes the enactment date. In addition, valuation allowances are established when necessary to reduce deferred tax assets and liabilities to the amounts expected to be realized. The Company has elected to account for global intangible low-taxed income (“GILTI”) as a period expense in the year the tax is incurred. The Company recognizes the financial statement benefit of an income tax position only after determining that the relevant taxing authority would more likely than not not 50% Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require application of significant judgment. The Company is subject to U.S. federal and various state, local and foreign jurisdictions. Due to the Company’s net operating loss carryforwards, the Company may In a referendum held on May 19, 2019, not 2020 2019 On March 27, 2020, 19 June 5, 2020 may Segments The Company operates in one not Approximately 26% and 19% of the Company’s total consolidated assets are located within the United States as of June 30, 2020 December 31, 2019, June 30, 2020 December 31, 2019, June 30, 2020 December 31, 2019, six June 30, 2020 2019, three June 30, 2020 2019, Impact of Recently Issued Accounting Standards In August 2018, 2018 13, Fair Value Measurement (Topic 820 January 1, 2020 not In December 2019, 2019 12, Simplifying the Accounting for Income Taxes 2019 12 740, 2019 12 December 15, 2020, not In June 2016, 2016 13, Financial Instruments-Credit Losses (Topic 326 December 15, 2022, not

Note 3 - Acquisitions

Note 3 - Acquisitions	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Business Combination Disclosure [Text Block]	3. Acquisitions MST Medical Surgery Technologies Ltd. Acquisition On September 23, 2018, two October 31, 2018, Under the terms of the MST Purchase Agreement, at the closing the Buyers purchased substantially all of the assets of MST. The acquisition price consisted of two second $6.6 one August 7, 2019, February 7, 2020. On July 3, 2019 October 15, 2019, 2019 December 31, 2019, Senhance Surgical Robotic System On September 21, 2015, €27.5 On December 30, 2016, second second €5.0 January 2017. €22.5 €15.0 June 30, 2020. third €15.0 €25.0 The fourth €2.5 December 31 December 31, 2017. June 30, 2020, fourth The Third Tranche payments will be accelerated in the event that (i) the Company or TransEnterix International is acquired, (ii) the Company significantly reduces or suspends selling efforts of the Senhance System, or (iii) the Company acquires a business that offers alternative products that are directly competitive with the Senhance System. The remaining amounts due to Sofar are included in contingent consideration as of June 30, 2020 December 31, 2019

Note 4 - Fair Value

Note 4 - Fair Value	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Fair Value Disclosures [Text Block]	4. Fair Value The carrying values of accounts receivable, accounts payable, and certain accrued expenses as of June 30, 2020 December 31, 2019, The Company held certain assets and liabilities that are required to be measured at fair value on a recurring basis. These assets and liabilities include cash and cash equivalents, restricted cash, contingent consideration and warrant liabilities. ASC 820 10 three one three ● Level 1, ● Level 2, 1, ● Level 3, The determination of where an asset or liability falls in the hierarchy requires significant judgment; however, the Company expects changes in classifications between levels will be rare. The Company did not 1, 2, 3 three six June 30, 2020 December 31, 2019. For assets and liabilities recorded at fair value, it is the Company’s policy to maximize the use of observable inputs and minimize the use of unobservable inputs when developing fair value measurements, in accordance with the fair value hierarchy. Fair value measurements for assets and liabilities where there exists limited or no may not may The following are the major categories of assets and liabilities measured at fair value on a recurring basis using quoted prices in active markets for identical assets (Level 1 2 3 June 30, 2020 (in thousands) Description Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets measured at fair value Cash and cash equivalents $ 15,603 $ - $ - $ 15,603 Restricted cash 627 - - 627 Total assets measured at fair value $ 16,230 $ - $ - $ 16,230 Liaiblities measured at fair value Contingent consideration $ - $ - $ 2,278 $ 2,278 Warrant liabilities - - 187 187 Total liabilities measured at fair value $ - $ - $ 2,465 $ 2,465 December 31, 2019 (in thousands) Description Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets measured at fair value Cash and cash equivalents $ 9,598 $ - $ - $ 9,598 Restricted cash 969 - - 969 Total assets measured at fair value $ 10,567 $ - $ - $ 10,567 Liaiblities measured at fair value Contingent consideration $ - $ - $ 1,084 $ 1,084 Warrant liabilities - - 2,388 2,388 Total liabilities measured at fair value $ - $ - $ 3,472 $ 3,472 The Company’s financial liabilities consisted of contingent consideration potentially payable to Sofar related to the Senhance Acquisition in September 2015 ( 3 3 three six June 30, 2020, three six June 30, 2019, On April 28, 2017, October 31, 2017. one thirteen December 11, 2019 9 may fifth The change in fair value of all outstanding Series B Warrants for the three June 30, 2020 2019 six June 30, 2020 2019 The Company uses a monte carlo monte carlo 2020 The following table summarizes the change in fair value, as determined by Level 3 six June 30, 2020: Fair Value Measurement at Reporting Date (Level 3) (in thousands) Common stock warrants Contingent consideration Balance at December 31, 2019 $ 2,388 $ 1,084 Exchange of warrants (2,470 ) - Change in fair value 269 1,268 Payment of contingent consideration - (74 ) Balance at June 30, 2020 $ 187 $ 2,278 Current portion $ - $ - Long-term portion 187 2,278 Balance at June 30, 2020 $ 187 $ 2,278

Note 5 - Inventories

Note 5 - Inventories	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Inventory Disclosure [Text Block]	5 . Inventories The components of inventories are as follows: June 30, 2020 December 31, 2019 (in thousands) Finished Goods $ 10,159 $ 9,737 Raw Materials 7,032 8,510 Total Inventories $ 17,191 $ 18,247 Current portion $ 10,857 $ 10,653 Long-term portion 6,334 7,594 Total inventories $ 17,191 $ 18,247 The Company recorded a write-down of obsolete inventory for the year-ended December 31, 2019 no three six June 30, 2020. three six June 30, 2019.

Note 6 - Goodwill, In-Process R

Note 6 - Goodwill, In-Process Research and Development and Intellectual Property	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	6. In-Process Research and Development and Intellectual Property In-Process Research and Development During the third 2019, December 31, 2019 no On March 13, 2020, The carrying value of the Company’s IPR&D assets and the change in the balance for the six June 30, 2020 In-Process Research and Development (in thousands) Balance at December 31, 2019 $ 2,470 Foreign currency translation impact (45 ) Transfer to developed technology (2,425 ) Balance at June 30, 2020 $ - Intellectual Property The components of gross intellectual property, accumulated amortization, and net intellectual property as of June 30, 2020 December 31, 2019 June 30, 2020 (in thousands) Gross Carrying Amount Accumulated Amortization Foreign Currency Translation Impact Net Carrying Amount Developed technology $ 68,838 $ (42,207 ) $ (1,117 ) $ 25,514 Technology and patents purchased 400 (133 ) 21 288 Total intellectual property $ 69,238 $ (42,340 ) $ (1,096 ) $ 25,802 December 31, 2019 (in thousands) Gross Carrying Amount Accumulated Amortization Foreign Currency Translation Impact Net Carrying Amount Developed technology $ 66,413 $ (36,918 ) $ (1,208 ) $ 28,287 Technology and patents purchased 400 (112 ) 21 309 Total intellectual property $ 66,813 $ (37,030 ) $ (1,187 ) $ 28,596 The weighted average remaining useful life of the developed technology and technology and patents purchased was 2.7 years and 6.8 years, respectively as of June 30, 2020.

Note 7 - Income Taxes

Note 7 - Income Taxes	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Income Tax Disclosure [Text Block]	7. Income Taxes Income taxes have been accounted for using the asset and liability method in accordance with ASC 740 December 31, 2020. not three June 30, 2020 2019 six June 30, 2020 2019 The Company incurred losses for the three six June 30, 2020 December 31, 2020. not not 2019 2020; no three six June 30, 2020 2019. The deferred tax benefit during the three June 30, 2020 2019, six June 30, 2020 2019, June 30, 2020 December 31, 2020. three June 30, 2020 2019, six June 30, 2020 2019 As of June 30, 2020, no

Note 8 - Notes Payable

Note 8 - Notes Payable	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	8. Notes Payable Pay check Protection Program The CARES Act was passed in the United States and signed into law on March 7, 2020 June 5, 2020 April 27, 2020, April 18, 2020 ( The Promissory Note has a two April 27, 2022, not 10 24 December 31, 2020 ( may twenty-four 60% may eight 24 no Any forgiveness of the Promissory Note will be subject to approval by the SBA and the Lender. The Company recognizes that its restructuring activities unrelated to COVID- 19 may not not may Hercules Loan Agreement On May 23, 2018, two 2019. The term loans bore interest at a rate equal to the greater of (i) 10.05% per annum (the “Fixed Rate”) and (ii) the Fixed Rate plus the prime rate (as reported in The Wall Street Journal) minus 5.00%. On the Initial Funding Date, the Company was obligated to pay a facility fee of $0.4 million, recorded as a debt discount. The Company also incurred other debt issuance costs totaling $1.1 million in conjunction with its entry into the Hercules Loan Agreement. In addition, the Company was permitted to prepay the term loans in full at any time, with a prepayment fee of 3.0% of the outstanding principal amount of the loan in the first second The Company’s obligations under the Hercules Loan Agreement were guaranteed by all current and future material foreign subsidiaries of the Company and were secured by a security interest in all of the assets of the Company and their current and future domestic subsidiaries and all of the assets of their current and future material foreign subsidiaries, including a security interest in the intellectual property. The Hercules Loan Agreement contained customary representations and covenants that, subject to exceptions, restricted the Company’s and its subsidiaries’ ability to do the following, among other things: declare dividends or redeem or repurchase equity interests; incur additional indebtedness and liens; make loans and investments; engage in mergers, acquisitions, and asset sales; transact with affiliates; undergo a change in control; add or change business locations; and engage in businesses that were not first x 90 On November 4, 2019, December 31, 2019.

Note 9 - Warrants

Note 9 - Warrants	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Warrants Disclosure [Text Block]	9 . Warrants The exercise prices and the number of shares issuable upon exercise of each of the outstanding Series B Warrants are subject to adjustment upon the occurrence of certain events, including, but not On February 24, 2020, As a result of the exercise price adjustment feature the exercise price of all outstanding Series B Warrants has been adjusted to $0.37 per share and the number of shares of common stock reserved for and issuable upon the exercise of outstanding Series B Warrants has been adjusted to 530,381 as of June 30, 2020. On March 10, 2020, one one 10 The Series C Warrants and Series D Warrants are equity classified. The fair value of the Series C Warrants and Series D Warrants on the issuance date was determined using a Black-Scholes Merton model. The unit proceeds were then allocated to the Common Stock, Series A Preferred Stock, Series C Warrants, and Series D Warrants, respectively, based on their relative fair values. As a result, the Company determined that a beneficial conversion feature was created by the difference between the effective conversion price of the preferred stock and the fair value of the Company's Common Stock as of the issuance date. The Company therefore recorded a beneficial conversion feature of $0.4 million as a deemed dividend included in additional paid-in capital and an immediate charge to earnings available to common stockholders for the three March 31, 2020. The following table summarizes outstanding warrant, including the Series B Warrants, the Series C Warrants, and the Series D Warrants as of June 30, 2020: Range of Exercise Prices Number of Warrants Outstanding Range of Expiration Dates $0.37 530,381 May 2022 $0.68 45,823,528 March 2021 - March 2025 $13.00 - $52.20 107,721 September 2021 - September 2027 46,461,630

Note 10 - Equity Offerings

Note 10 - Equity Offerings	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	10. Equity Offerings On August 12, 2019, “2019 may “2019 3, May 2020. The following table summarizes the total sales under the ATM Offering for the period indicated (in thousands except for share and per share amounts): ATM Offering For the Six Months Ended June 30, 2020 Total shares of common stock sold 6,687,846 Average price per share $ 1.73 Gross proceeds $ 11,558 Commissions earned by Cantor 346 Net proceeds $ 11,212 Public Offering s of Securities On March 10, 2020, March 2020 one one one first one one fifth one one one one no not The shares of Series A Preferred Stock rank on par with the shares of the common stock, in each case, as to dividend rights and distributions of assets upon liquidation, dissolution or winding up of the Company. With certain statutory exceptions, as described in the Series A Preferred Stock Certificate of Designation, the shares of Series A Preferred Stock have no one The net proceeds to the Company from the March 2020 7.9 six June 30, 2020. 4.9 six June 30, 2020, 3, May 2020. 1 May 27, 2020. On July 6, 2020, 14

Note 11 - Restructuring

Note 11 - Restructuring	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	11. Restructuring During the fourth 2019, December 31, 2019. six June 30, 2020, 2020 2020. Future payments under the restructuring plan are expected to conclude in 2020 six June 30, 2020, Restructuring Liability (in thousands) Balance at December 31, 2019 $ 882 Amount charged to operating expenses 858 Cash payments (752 ) Balance at June 30, 2020 $ 988

Note 12 - Basic and Diluted Net

Note 12 - Basic and Diluted Net Loss Per Share	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Earnings Per Share [Text Block]	12. Basic and Diluted Net Loss per Share Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Diluted potential common shares consist of incremental shares issuable upon exercise of stock options, restricted stock units, warrants and preferred stock. For the six June 30, 2020, three six June 30, 2020 For the three six June 30, 2019, three six June 30, 2019, As of June 30, 2020, June 30, 2019,

Note 13 - Commitments and Conti

Note 13 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	13. Commitments and Contingencies Contingent Consideration As discussed in Note 3, September 2015, may December 30, 2016, €5.0 €5.0 June 30, 2020 December 31, 2019, Legal Proceedings No six three June 30, 2020 2019.

Note 14 - Subsequent Events

Note 14 - Subsequent Events	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	14. Subsequent Events On July 6, 2020, “July 2020 July 2020 3 No. 333 236200 Following the July 2020 In July 2020, first 2021, two five five 125 three March 31, 2021.

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The Company has prepared the accompanying unaudited interim condensed consolidated financial statements in accordance with the instructions to Form 10 not 10 10 not may 2019 10 not On December 11, 2019, one December 12, 2019. No Unless otherwise noted, all share and per share data referenced in the condensed consolidated financial statements and the notes thereto have been retroactively adjusted to reflect the Reverse Stock Split. As a result of the Reverse Stock Split, certain amounts in the condensed consolidated financial statements and the notes thereto may
Substantial Doubt about Going Concern [Policy Text Block]	Liquidity and Going Concern The Company's condensed consolidated financial statements are prepared using U.S. GAAP applicable to a going concern, which contemplate the realization of assets and liquidation of liabilities in the normal course of business. The Company had an accumulated deficit of $694.0 million as of June 30, 2020 June 30, 2020. not The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. In order to continue as a going concern, the Company will need, among other things, additional capital resources. Traditionally, the Company has raised additional capital through equity offerings, including raising net proceeds of $13.5 million in the March 2020 10 July 2020 14 April 2020 may 8 may may one not not 19 At June 30, 2020, one not may
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include identifiable intangible assets and goodwill, contingent consideration, warrant liabilities, stock compensation expense, revenue recognition, accounts receivable reserves, excess and obsolete inventory reserves, inventory classification between current and non-current, and deferred tax asset valuation allowances. The COVID- 19 19 19 19 19
Consolidation, Policy [Policy Text Block]	Principles of Consolidation and Foreign Currency Considerations The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its direct and indirect wholly owned subsidiaries, SafeStitch LLC, TransEnterix Surgical, Inc., TransEnterix International, Inc., TransEnterix Italia S.r.l., TransEnterix Europe S.à.R.L, TransEnterix Asia Pte. Ltd., TransEnterix Taiwan Ltd., TransEnterix Japan KK, TransEnterix Israel Ltd. and TransEnterix Netherlands B.V. All material inter-company accounts and transactions have been eliminated in consolidation. The functional currency of the Company’s operational foreign subsidiaries is predominantly the Euro. The assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at the average exchange rates prevailing during the period. The cumulative translation effect for a subsidiary using a functional currency other than the U.S. dollar is included in accumulated other comprehensive income or loss as a separate component of stockholders’ equity. The Company’s intercompany accounts are denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the remeasurement of intercompany receivables that the Company considers to be of a long-term investment nature are recorded as a cumulative translation adjustment in accumulated other comprehensive income or loss as a separate component of stockholders’ equity, while gains and losses resulting from the remeasurement of intercompany receivables from a foreign subsidiary for which the Company anticipates settlement in the foreseeable future are recorded in the condensed consolidated statements of operations and comprehensive loss. The net gains and losses included in net loss in the condensed consolidated statements of operations and comprehensive loss for the three six June 30, 2020 2019 not
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations and Credit Risk The Company’s principal financial instruments subject to potential concentration of credit risk are cash and cash equivalents, including amounts held in money market accounts. The Company places cash deposits with a federally insured financial institution. The Company maintains its cash at banks and financial institutions it considers to be of high credit quality; however, the Company’s domestic cash deposits may may not not not The Company’s accounts receivable are derived from sales to customers located throughout the world. The Company evaluates its customers’ financial condition and, generally, requires no no eight June 30, 2020. eight December 31, 2019. The Company had seven three June 30, 2020 five three June 30, 2019. nine six June 30, 2020 two six June 30, 2019.
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with original maturities of 90 Restricted cash at June 30, 2020 December 31, 2019 2018.
Receivable [Policy Text Block]	Accounts Receivable Accounts receivable are recorded at net realizable value, which includes an allowance for estimated uncollectible accounts. The allowance for uncollectible accounts was determined on a customer specific basis based on deemed collectability. The allowance for doubtful accounts was $1.7 June 30, 2020 December 31, 2019.
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost (determined on a first first not Any inventory on hand at the measurement date in excess of the Company's current requirements based on anticipated levels of sales is classified as long-term on the Company's condensed consolidated balance sheets. The Company’s classification of long-term inventory requires it to estimate the portion of on hand inventory that can be realized over the upcoming twelve
Goodwill and Intangible Assets, Policy [Policy Text Block]	Identifiable Intangible Assets and Goodwill Definite-Lived Intangible Assets - Intellectual Property Intellectual property consists of purchased patent rights and developed technology acquired as part of a business acquisition. Developed technology includes reclassified IPR&D assets related to (i) the Senhance System acquired in 2015 2017 2018 2020. The Company periodically evaluates intellectual property for impairment whenever events or changes in circumstances indicate that the carrying amount may not No six June 30, 2020 2019. Indefinite-Lived Intangible Assets – In-Process Research and Development In-process research and development (“IPR&D”) assets represent the fair value assigned to technologies that were acquired, which at the time of acquisition have not no The Company performed an impairment test of its IPR&D at the end of the third 2019 third 2019, December 31, 2019 no The Company reclassifies IPR&D assets to intellectual property when development is complete, which generally occurs upon regulatory approval and the Company is able to commercialize products. The completed IPR&D assets are then classified as definite-lived intangible assets (developed technology) and are amortized based on their estimated useful lives at that point in time. If development is terminated or abandoned, the Company may The Company did not three six June 30, 2020 2019. June 30, 2020, Goodwill Goodwill of $93.8 million was recorded in connection with a September 2013 3 The Company performs an annual impairment test of goodwill at December 31, one may not third 2019,
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment consists primarily of machinery, manufacturing equipment, demonstration equipment, computer equipment, furniture, and leasehold improvements, which are recorded at cost. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows: Machinery, manufacturing and demonstration equipment (in years) 3 - 5 Computer equipment (in years) 3 Furniture (in years) 5 Leasehold improvements Lesser of lease term or 3 to 10 years Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred. The Company reviews its property and equipment assets for possible impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not not three six June 30, 2020 2019.
Contingent Consideration [Policy Text Block]	Contingent Consideration Contingent cash consideration arising from business combinations is recorded as a liability and is the estimate of the fair value of potential milestone payments related to those acquisitions. Contingent consideration is measured at fair value using a discounted cash flow model using significant unobservable inputs including the probability of achieving each of the potential milestones, future Euro-to-USD exchange rates, and an estimated discount rate associated with the risks of the expected cash flows attributable to the various milestones. Significant increases or decreases in any of the probabilities of success or changes in expected achievement of any of these milestones would result in a significantly higher or lower fair value of these milestones, respectively, and commensurate changes to the associated liability. The contingent consideration is revalued at each reporting period and changes in fair value are recognized in the condensed consolidated statements of operations and comprehensive loss.
Warrant Liabilities [Policy Text Block]	Warrant Liabilities The Company’s Series B Warrants (see Note 9 4
Revenue [Policy Text Block]	Revenue Recognition The Company’s revenue consists of product revenue resulting from the sale of Systems, System components, instruments and accessories, and service revenue. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company's revenues are measured based on consideration specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities. The Company’s System sale arrangements generally include a five first four The Company’s System sale arrangements generally contain multiple products and services. For these consolidated sale arrangements, the Company accounts for individual products and services as separate performance obligations if they are distinct, which is if a product or service is separately identifiable from other items in the consolidated package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company’s System sale arrangements may For arrangements that contain multiple performance obligations, revenue is allocated to each performance obligation based on its relative estimated standalone selling price. When available, standalone selling prices are based on observable prices at which the Company separately sells the products or services; however due to limited sales to date, standalone selling prices generally are not not The Company enters into lease arrangements with certain qualified customers. Revenue related to arrangements including lease elements are allocated to lease and non-lease elements based on their relative standalone selling prices. Lease elements generally include a Senhance System, while non-lease elements generally include service, instruments, and accessories. For some lease arrangements, the customers are provided with the right to purchase the leased System at some point during and/or at the end of the lease term. In some arrangements lease payments are based on the usage of the System. In determining whether a transaction should be classified as a sales-type or operating lease, the Company considers the following terms at lease commencement: ( 1 2 3 4 5 no June 30, 2020 The Company recognizes revenues as the performance obligations are satisfied by transferring control of the product or service to a customer. The Company generally recognizes revenue for the performance obligations as follows: ● System sales. For Systems and System components sold directly to end customers, revenue is recognized when the Company transfers control to the customer, which is generally at the point when acceptance occurs that indicates customer acknowledgment of delivery or installation, depending on the terms of the arrangement. For Systems sold through distributors, for which distributors are responsible for installation, revenue is recognized generally at the time of shipment. The Company’s System arrangements generally do not one not ● Lease arrangements. Revenue related to lease elements from operating lease arrangements is generally recognized on a straight-line basis over the lease term or based upon System usage and is presented as product revenue. ● Instruments and accessories. Revenue from sales of instruments and accessories is recognized when control is transferred to the customers, which generally occurs at the time of shipment, but also occurs at the time of delivery depending on the customer arrangement. ● Service. Service revenue is recognized ratably over the term of the service period as the customers benefit from the service throughout the service period. Revenue related to services performed on a time-and-materials basis is recognized when performed. The following table presents revenue disaggregated by type and geography (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 U.S. Systems $ 45 $ - $ 75 $ - Instruments and accessories 7 25 67 25 Services 103 127 171 260 Total U.S. revenue 155 152 313 285 Outside of U.S. ("OUS") Systems 117 2,782 127 4,065 Instruments and accessories 146 535 288 1,081 Services 237 170 527 389 Total OUS revenue 500 3,487 942 5,535 Total Systems 162 2,782 202 4,065 Instruments and accessories 153 560 355 1,106 Services 340 297 698 649 Total revenue $ 655 $ 3,639 $ 1,255 $ 5,820 The Company recognizes sales by geographic area based on the country in which the customer is based. Operating lease revenue is included in the above table and was approximately $0.1 million and $0 for the three June 30, 2020 2019, six June 30, 2020 2019, Transaction price allocated to remaining performance obligations relates to amounts allocated to products and services for which the revenue has not June 30, 2020 December 31, 2019, The Company invoices its customers based on the billing schedules in its sales arrangements. Contract assets for the periods presented primarily represent the difference between the revenue that was recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements. Contract assets are included in accounts receivable and totaled $0.1 million and $0.2 million as of June 30, 2020 December 31, 2019, not three June 30, 2020 2019, six June 30, 2020 2019, three six June 30, 2019 2017 first second 2019. June 30, 2020 one three In connection with assets recognized from the costs to obtain a contract with a customer, the Company determined that the sales incentive programs for its sales team do not not
Cost of Goods and Service [Policy Text Block]	Cost of Revenue Cost of revenue consists of contract manufacturing, materials, labor and manufacturing overhead incurred internally to produce the products. Shipping and handling costs incurred by the Company are included in cost of revenue. During the three June 30, 2020 2019, six June 30, 2020 2019,
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs Research and development expenses primarily consist of engineering, product development and regulatory expenses, incurred in the design, development, testing and enhancement of our products. Research and development costs are expensed as incurred.
Share-based Payment Arrangement [Policy Text Block]	Stock-Based Compensation The Company follows ASC 718 not not not The fair value of restricted stock units is determined by the market price of the Company’s common stock on the date of grant. Compensation expense for stock-based compensation was approximately $1.9 million and $3.4 million for the three June 30, 2020 2019, six June 30, 2020 2019, On June 8, 2020, 2020 one The awards to the executive officers include the 2020 $1.00 twenty three The awards were all made under the Company’s Amended and Restated Incentive Compensation Plan. An aggregate of 2,061,289 shares of common stock underlie these awards if they fully vest.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets or liabilities for the temporary differences between financial reporting and tax basis of the Company’s assets and liabilities, and for tax carryforwards at enacted statutory rates in effect for the years in which the asset or liability is expected to be realized. The effect on deferred taxes of a change in tax rates is recognized in income during the period that includes the enactment date. In addition, valuation allowances are established when necessary to reduce deferred tax assets and liabilities to the amounts expected to be realized. The Company has elected to account for global intangible low-taxed income (“GILTI”) as a period expense in the year the tax is incurred. The Company recognizes the financial statement benefit of an income tax position only after determining that the relevant taxing authority would more likely than not not 50% Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require application of significant judgment. The Company is subject to U.S. federal and various state, local and foreign jurisdictions. Due to the Company’s net operating loss carryforwards, the Company may In a referendum held on May 19, 2019, not 2020 2019 On March 27, 2020, 19 June 5, 2020 may
Segment Reporting, Policy [Policy Text Block]	Segments The Company operates in one not Approximately 26% and 19% of the Company’s total consolidated assets are located within the United States as of June 30, 2020 December 31, 2019, June 30, 2020 December 31, 2019, June 30, 2020 December 31, 2019, six June 30, 2020 2019, three June 30, 2020 2019,
New Accounting Pronouncements, Policy [Policy Text Block]	Impact of Recently Issued Accounting Standards In August 2018, 2018 13, Fair Value Measurement (Topic 820 January 1, 2020 not In December 2019, 2019 12, Simplifying the Accounting for Income Taxes 2019 12 740, 2019 12 December 15, 2020, not In June 2016, 2016 13, Financial Instruments-Credit Losses (Topic 326 December 15, 2022, not

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Schedule of Property Plant and Equipment Useful Life [Table Text Block]	Machinery, manufacturing and demonstration equipment (in years) 3 - 5 Computer equipment (in years) 3 Furniture (in years) 5 Leasehold improvements Lesser of lease term or 3 to 10 years
Disaggregation of Revenue [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 U.S. Systems $ 45 $ - $ 75 $ - Instruments and accessories 7 25 67 25 Services 103 127 171 260 Total U.S. revenue 155 152 313 285 Outside of U.S. ("OUS") Systems 117 2,782 127 4,065 Instruments and accessories 146 535 288 1,081 Services 237 170 527 389 Total OUS revenue 500 3,487 942 5,535 Total Systems 162 2,782 202 4,065 Instruments and accessories 153 560 355 1,106 Services 340 297 698 649 Total revenue $ 655 $ 3,639 $ 1,255 $ 5,820

Note 4 - Fair Value (Tables)

Note 4 - Fair Value (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	June 30, 2020 (in thousands) Description Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets measured at fair value Cash and cash equivalents $ 15,603 $ - $ - $ 15,603 Restricted cash 627 - - 627 Total assets measured at fair value $ 16,230 $ - $ - $ 16,230 Liaiblities measured at fair value Contingent consideration $ - $ - $ 2,278 $ 2,278 Warrant liabilities - - 187 187 Total liabilities measured at fair value $ - $ - $ 2,465 $ 2,465 December 31, 2019 (in thousands) Description Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets measured at fair value Cash and cash equivalents $ 9,598 $ - $ - $ 9,598 Restricted cash 969 - - 969 Total assets measured at fair value $ 10,567 $ - $ - $ 10,567 Liaiblities measured at fair value Contingent consideration $ - $ - $ 1,084 $ 1,084 Warrant liabilities - - 2,388 2,388 Total liabilities measured at fair value $ - $ - $ 3,472 $ 3,472
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Fair Value Measurement at Reporting Date (Level 3) (in thousands) Common stock warrants Contingent consideration Balance at December 31, 2019 $ 2,388 $ 1,084 Exchange of warrants (2,470 ) - Change in fair value 269 1,268 Payment of contingent consideration - (74 ) Balance at June 30, 2020 $ 187 $ 2,278 Current portion $ - $ - Long-term portion 187 2,278 Balance at June 30, 2020 $ 187 $ 2,278

Note 5 - Inventories (Tables)

Note 5 - Inventories (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Schedule of Inventory, Current [Table Text Block]	June 30, 2020 December 31, 2019 (in thousands) Finished Goods $ 10,159 $ 9,737 Raw Materials 7,032 8,510 Total Inventories $ 17,191 $ 18,247 Current portion $ 10,857 $ 10,653 Long-term portion 6,334 7,594 Total inventories $ 17,191 $ 18,247

Note 6 - Goodwill, In-Process_2

Note 6 - Goodwill, In-Process Research and Development and Intellectual Property (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	In-Process Research and Development (in thousands) Balance at December 31, 2019 $ 2,470 Foreign currency translation impact (45 ) Transfer to developed technology (2,425 ) Balance at June 30, 2020 $ - June 30, 2020 (in thousands) Gross Carrying Amount Accumulated Amortization Foreign Currency Translation Impact Net Carrying Amount Developed technology $ 68,838 $ (42,207 ) $ (1,117 ) $ 25,514 Technology and patents purchased 400 (133 ) 21 288 Total intellectual property $ 69,238 $ (42,340 ) $ (1,096 ) $ 25,802 December 31, 2019 (in thousands) Gross Carrying Amount Accumulated Amortization Foreign Currency Translation Impact Net Carrying Amount Developed technology $ 66,413 $ (36,918 ) $ (1,208 ) $ 28,287 Technology and patents purchased 400 (112 ) 21 309 Total intellectual property $ 66,813 $ (37,030 ) $ (1,187 ) $ 28,596

Note 9 - Warrants (Tables)

Note 9 - Warrants (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Range of Exercise Prices Number of Warrants Outstanding Range of Expiration Dates $0.37 530,381 May 2022 $0.68 45,823,528 March 2021 - March 2025 $13.00 - $52.20 107,721 September 2021 - September 2027 46,461,630

Note 10 - Equity Offerings (Tab

Note 10 - Equity Offerings (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Schedule of Sales Under Sales Agency Agreement [Table Text Block]	ATM Offering For the Six Months Ended June 30, 2020 Total shares of common stock sold 6,687,846 Average price per share $ 1.73 Gross proceeds $ 11,558 Commissions earned by Cantor 346 Net proceeds $ 11,212

Note 11 - Restructuring (Tables

Note 11 - Restructuring (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Restructuring and Related Costs [Table Text Block]	Restructuring Liability (in thousands) Balance at December 31, 2019 $ 882 Amount charged to operating expenses 858 Cash payments (752 ) Balance at June 30, 2020 $ 988

Note 1 - Business Overview (Det

Note 1 - Business Overview (Details Textual) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2020	Dec. 31, 2019
Restructuring Charges, Total	$ 8,800	$ 858
Other Restructuring Costs			$ 7,400
Restructuring Reserve, Ending Balance	882	988	$ 882
Accrued Expense [Member]
Restructuring Reserve, Ending Balance		1,000
Cost of Sales [Member]
Other Restructuring Costs	7,400
Restructuring and Other Charges [Member]
Severance Costs	$ 1,400	$ 900

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies 1 (Details Textual)	Jul. 06, 2020USD ($)	Jun. 08, 2020USD ($)shares	Apr. 27, 2020USD ($)	Mar. 10, 2020USD ($)	Dec. 11, 2019shares	Jun. 30, 2020USD ($)shares	Dec. 31, 2019USD ($)shares	Sep. 30, 2019USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)shares	Jun. 30, 2019USD ($)	Dec. 31, 2019USD ($)shares	Dec. 10, 2019shares
Common Stock, Shares, Outstanding, Ending Balance (in shares) | shares					20,200,000	56,902,140	20,691,301			56,902,140		20,691,301	261,900,000
Retained Earnings (Accumulated Deficit), Ending Balance						$ (694,038,000)	$ (663,600,000)			$ (694,038,000)		$ (663,600,000)
Working Capital						24,300,000				24,300,000
Proceeds from Issuance of Equity Net										13,525,000	$ 0
Cash and Cash Equivalents, at Carrying Value, Ending Balance						15,603,000	9,598,000			15,603,000		9,598,000
Restricted Cash and Cash Equivalents, Noncurrent, Total						600,000	1,000,000			600,000		1,000,000
Accounts Receivable, Allowance for Credit Loss, Ending Balance						1,700,000	1,700,000			1,700,000		1,700,000
Impairment of Intangible Assets, Finite-lived										$ 0	0
Goodwill, Impairment Loss							79,000,000
Period Of Service Sale Arrangement (Year)										5 years
Period of Service Sale Arrangement at Stated Service Price (Year)										4 years
Operating Lease, Lease Income, Total						100,000			$ 0	$ 200,000	0
Revenue, Remaining Performance Obligation, Amount						3,000,000	3,700,000			3,000,000		3,700,000
Contract with Customer, Asset, after Allowance for Credit Loss, Current, Total						100,000	200,000			100,000		200,000
Contract with Customer, Liability, Revenue Recognized						400,000			400,000	600,000	700,000
Inventory Write-down						0			800,000	0	761,000
Share-based Payment Arrangement, Expense						1,900,000			3,400,000	$ 3,900,000	6,300,000
Share-based Compensation Arrangement by Share-based Payment Award, Options and RSUs, Grants in Period, Grant Date Value Per Non-employee Director		$ 45,000
Common Stock, Capital Shares Reserved for Future Issuance (in shares) | shares		2,061,289
Number of Operating Segments										1
Assets, Total						75,974,000	74,779,000			$ 75,974,000		74,779,000
Non-US [Member]
Assets, Total						56,400,000	60,500,000			56,400,000		$ 60,500,000
System Sold in 2017 [Member]
Contract with Customer, Liability, Revenue Recognized									1,300,000		1,300,000
Safe Stitch Medical Inc [Member]
Goodwill, Ending Balance						93,800,000				93,800,000
Senhance Surgical Robotic System Acquisition [Member]
Goodwill, Ending Balance						38,300,000				38,300,000
Medical Surgery Technologies Limited [Member]
Goodwill, Ending Balance						9,600,000				$ 9,600,000
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options and RSUs, Grants in Period, Grant Date Value		$ 5,000
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options and RSUs, Grants in Period, Grant Date Value		$ 10,000
Patents [Member]
Finite-Lived Intangible Asset, Useful Life (Year)										10 years
Developed Technology Rights [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)										5 years
Developed Technology Rights [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)										7 years
In Process Research and Development [Member]
Impairment of Intangible Assets, Finite-lived						$ 0	$ 0	$ 7,900,000	$ 0	$ 0	$ 0
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Eight Customers [Member]
Number of Major Customers										8		8
Concentration Risk, Percentage										76.00%		85.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Seven Customers [Member]
Number of Major Customers						7
Concentration Risk, Percentage						60.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Five Customers [Member]
Number of Major Customers									5
Concentration Risk, Percentage									91.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Nine Customers [Member]
Number of Major Customers										9
Concentration Risk, Percentage										65.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Two Customers [Member]
Number of Major Customers											2
Concentration Risk, Percentage											76.00%
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | UNITED STATES
Concentration Risk, Percentage						24.00%			4.00%	25.00%	5.00%
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | Europe [Member]
Concentration Risk, Percentage						56.00%			48.00%	52.00%	42.00%
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | Asia [Member]
Concentration Risk, Percentage						20.00%			47.00%	23.00%	53.00%
Assets, Total [Member] | Geographic Concentration Risk [Member] | UNITED STATES
Concentration Risk, Percentage										26.00%		19.00%
Assets, Total [Member] | Geographic Concentration Risk [Member] | Non-US [Member]
Concentration Risk, Percentage										74.00%		81.00%
Paycheck Protection Program CARES Act [Member]
Proceeds from Issuance of Long-term Debt, Total			$ 2,815,200
Public Offering [Member]
Proceeds from Issuance of Equity Net				$ 13,500,000
Public Offering [Member] | Subsequent Event [Member]
Proceeds from Issuance of Equity Net	$ 13,700,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio					13

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies 2 (Details Textual) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-07-01	Jun. 30, 2020
Minimum [Member]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	1 year
Maximum [Member]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)	3 years

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)	6 Months Ended
	Jun. 30, 2020
Machinery, Manufacturing and Demonstration Equipment [Member] | Minimum [Member]
Property and equipment, estimated useful lives (Year)	3 years
Machinery, Manufacturing and Demonstration Equipment [Member] | Maximum [Member]
Property and equipment, estimated useful lives (Year)	5 years
Computer Equipment [Member]
Property and equipment, estimated useful lives (Year)	3 years
Furniture and Fixtures [Member]
Property and equipment, estimated useful lives (Year)	5 years
Leasehold Improvements [Member] | Minimum [Member]
Property and equipment, estimated useful lives (Year)	3 years
Leasehold Improvements [Member] | Maximum [Member]
Property and equipment, estimated useful lives (Year)	10 years

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Revenue Disaggregated by Type and Geography (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenue	$ 655	$ 3,639	$ 1,255	$ 5,820
Systems [Member]
Revenue	162	2,782	202	4,065
Instruments and Accessories [Member]
Revenue	153	560	355	1,106
Service [Member]
Revenue	340	297	698	649
UNITED STATES
Revenue	155	152	313	285
UNITED STATES | Systems [Member]
Revenue	45	0	75	0
UNITED STATES | Instruments and Accessories [Member]
Revenue	7	25	67	25
UNITED STATES | Service [Member]
Revenue	103	127	171	260
Non-US [Member]
Revenue	500	3,487	942	5,535
Non-US [Member] | Systems [Member]
Revenue	117	2,782	127	4,065
Non-US [Member] | Instruments and Accessories [Member]
Revenue	146	535	288	1,081
Non-US [Member] | Service [Member]
Revenue	$ 237	$ 170	$ 527	$ 389

Note 3 - Acquisitions (Details

Note 3 - Acquisitions (Details Textual) $ in Thousands, € in Millions	Oct. 15, 2019USD ($)	Aug. 07, 2019USD ($)shares	Oct. 31, 2018USD ($)shares	Dec. 30, 2016EUR (€)shares	Sep. 21, 2015USD ($)shares	Sep. 21, 2015EUR (€)shares	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2020EUR (€)	Jun. 30, 2019USD ($)	Dec. 31, 2019USD ($)	Jun. 30, 2020EUR (€)
Gain (Loss) on Disposition of Assets, Total							$ 0	$ 0	$ 0		$ (97)
Business Combination, Contingent Consideration, Liability, Total							2,278		2,278			$ 1,084
Payment for Contingent Consideration Liability, Financing Activities									74		$ 0
Auto Lap [Member]
Disposal Group, Including Discontinued Operation, Consideration	$ 17,000
Proceeds from Sale of Productive Assets, Total	16,000
Disposal Group Including Discontinued Operation Consideration Receivable	$ 1,000
Gain (Loss) on Disposition of Assets, Total												16,000
Medical Surgery Technologies Limited [Member]
Payments to Acquire Businesses, Gross			$ 5,800
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | shares		370,423	242,310
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable		$ 6,600
Senhance Surgical Robotic System Acquisition [Member]
Payments to Acquire Businesses, Gross					$ 25,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | shares				286,360	1,195,647	1,195,647
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | €				€ 5
Business Combination, Consideration Transferred, Liabilities Incurred | €						€ 27.5
Business Combination, Contingent Consideration, Liability, Total							$ 2,300		$ 2,300			$ 1,100
Senhance Surgical Robotic System Acquisition [Member] | Second Tranche [Member]
Business Combination, Contingent Consideration, Liability, Total | €				€ 22.5
Payment for Contingent Consideration Liability, Financing Activities | €										€ 15
Senhance Surgical Robotic System Acquisition [Member] | Third Tranche [Member]
Business Combination, Contingent Consideration, Liability, Total | €													€ 15
Senhance Surgical Robotic System Acquisition [Member] | Third Tranche [Member] | Minimum [Member]
Business Combination Contingent Consideration Arrangements Target Revenue | €										€ 25
Senhance Surgical Robotic System Acquisition [Member] | Fourth Tranche [Member]
Business Combination, Contingent Consideration, Liability, Total | €						€ 2.5

Note 4 - Fair Value (Details Te

Note 4 - Fair Value (Details Textual) $ / shares in Units, $ in Thousands	Dec. 11, 2019	Apr. 28, 2017$ / sharesshares	Jun. 30, 2020USD ($)$ / shares	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)$ / shares	Jun. 30, 2019USD ($)
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability | $			$ 212	$ 960	$ 1,268	$ 1,958
Number of Units Sold (in shares)		24,900,000
Number of Shares in Each Unit (in shares)		0.077
Shares Issued, Price Per Share (in dollars per share) | $ / shares		$ 1
Fair Value Adjustment of Warrants | $			$ 114	(2,528)	$ 269	(2,422)
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	13
Series A Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		0.077
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 13
Series B Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		0.058
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 13	$ 0.37		$ 0.37
Fair Value Adjustment of Warrants | $			$ 100	$ (2,500)	$ 300	$ (2,400)

Note 4 - Fair Value - Summary o

Note 4 - Fair Value - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Cash and cash equivalents	$ 15,603	$ 9,598
Restricted cash	627	969
Total assets measured at fair value	16,230	10,567
Contingent consideration	2,278	1,084
Warrant liabilities	187	2,388
Total liabilities measured at fair value	2,465	3,472
Fair Value, Inputs, Level 1 [Member]
Cash and cash equivalents	15,603	9,598
Restricted cash	627	969
Total assets measured at fair value	16,230	10,567
Contingent consideration	0	0
Warrant liabilities	0	0
Total liabilities measured at fair value	0	0
Fair Value, Inputs, Level 2 [Member]
Cash and cash equivalents	0	0
Restricted cash	0	0
Total assets measured at fair value	0	0
Contingent consideration	0	0
Warrant liabilities	0	0
Total liabilities measured at fair value	0	0
Fair Value, Inputs, Level 3 [Member]
Cash and cash equivalents	0	0
Restricted cash	0	0
Total assets measured at fair value	0	0
Contingent consideration	2,278	1,084
Warrant liabilities	187	2,388
Total liabilities measured at fair value	$ 2,465	$ 3,472

Note 4 - Fair Value - Summary_2

Note 4 - Fair Value - Summary of Change in Fair Value for Warrants and Contingent Consideration (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)
Warrant [Member]
Balance	$ 2,388
Settlement	(2,470)
Change in fair value	269
Balance	187
Current portion	0
Long-term portion	187
Contingent Consideration [Member]
Balance	1,084
Settlement	(74)
Change in fair value	1,268
Balance	2,278
Current portion	0
Long-term portion	$ 2,278

Note 5 - Inventories (Details T

Note 5 - Inventories (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Other Restructuring Costs					$ 7,400
Inventory Write-down	$ 0	$ 800	$ 0	$ 761
Systems [Member]
Inventory Write-down		$ 800			$ 1,500

Note 5 - Inventories - Componen

Note 5 - Inventories - Components of Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Finished Goods	$ 10,159	$ 9,737
Raw Materials	7,032	8,510
Total Inventories	17,191	18,247
Current portion	10,857	10,653
Long-term portion	$ 6,334	$ 7,594

Note 6 - Goodwill, In-Process_3

Note 6 - Goodwill, In-Process Research and Development and Intellectual Property (Details Textual) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Impairment of Intangible Assets, Finite-lived					$ 0	$ 0
In Process Research and Development [Member]
Impairment of Intangible Assets, Finite-lived	$ 0	$ 0	$ 7,900	$ 0	$ 0	$ 0
Developed Technology Rights [Member] | Weighted Average [Member]
Finite-Lived Intangible Assets, Remaining Amortization Period (Year)					2 years 8 months 12 days
Technology-Based Intangible Assets [Member] | Weighted Average [Member]
Finite-Lived Intangible Assets, Remaining Amortization Period (Year)					6 years 9 months 18 days

Note 6 - Goodwill, In-Process_4

Note 6 - Goodwill, In-Process Research and Development and Intellectual Property - In-Process Research and Development and Intellectual Property (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets, Net	$ 28,596
Finite-Lived Intangible Assets, Net	25,802
Finite-Lived Intangible Assets, Gross	69,238	$ 66,813
Finite-Lived Intangible Assets, Accumulated Amortization	(42,340)	(37,030)
Finite-Lived Intangible Assets, Foreign Currency Translation Impact	(1,096)	(1,187)
In Process Research and Development [Member]
Finite-Lived Intangible Assets, Net	2,470
Foreign currency translation impact	(45)
Transfer to developed technology	(2,425)
Finite-Lived Intangible Assets, Net	0
Developed Technology Rights [Member]
Finite-Lived Intangible Assets, Net	28,287
Finite-Lived Intangible Assets, Net	25,514
Finite-Lived Intangible Assets, Gross	68,838	66,413
Finite-Lived Intangible Assets, Accumulated Amortization	(42,207)	(36,918)
Finite-Lived Intangible Assets, Foreign Currency Translation Impact	(1,117)	(1,208)
Technology-Based Intangible Assets [Member]
Finite-Lived Intangible Assets, Net	309
Finite-Lived Intangible Assets, Net	288
Finite-Lived Intangible Assets, Gross	400	400
Finite-Lived Intangible Assets, Accumulated Amortization	(133)	(112)
Finite-Lived Intangible Assets, Foreign Currency Translation Impact	$ 21	$ 21

Note 7 - Income Taxes (Details

Note 7 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2020
Effective Income Tax Rate Reconciliation, Percent, Total	4.80%	4.10%	4.40%	3.40%
Deferred Income Tax Expense (Benefit), Total	$ 700	$ 900	$ 1,400	$ 1,500
Current Income Tax Expense (Benefit), Total	$ 10	$ 20	$ 30	$ 30
Forecast [Member]
Effective Income Tax Rate Reconciliation, Percent, Total					2.30%

Note 8 - Notes Payable (Details

Note 8 - Notes Payable (Details Textual) - USD ($)	Apr. 27, 2020	Nov. 04, 2019	May 23, 2018
Hercules Loan Agreement [Member]
Extinguishment of Debt, Amount		$ 16,400,000
Payment for Debt Extinguishment or Debt Prepayment Cost		1,400,000
Gain (Loss) on Extinguishment of Debt, Total		$ (1,000,000)
Paycheck Protection Program CARES Act [Member]
Proceeds from Issuance of Long-term Debt, Total	$ 2,815,200
Debt Instrument, Term (Year)	2 years
Debt Instrument, Interest Rate, Stated Percentage	1.00%
Hercules Loan Agreement [Member]
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate			10.05%
Debt Instrument, Fee Amount			$ 400,000
Debt Issuance Costs, Net, Total			$ 1,100,000
Percentage of Prepayment Fee, First Year After Initial Funding Date			3.00%
Percentage of Prepayment Fee, Second Year After Initial Funding Date			2.00%
Percentage of Prepayment Fee, Third Year After Initial Funding Date and Thereafter			1.00%
Debt Instrument, Prepayment, Final Fee, Percentage			6.95%
Percentage of Outstanding Principal Balance of Term Loan Required to be Maintained			120.00%
Percentage of Maintained Cash and Investment Property in Accounts of Aggregate Cash of Parent and Subsidiaries			80.00%
Debt Instrument, Collateral Amount			$ 2,000,000
Hercules Loan Agreement [Member] | Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate			5.00%

Note 9 - Warrants (Details Text

Note 9 - Warrants (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Feb. 24, 2020	Mar. 31, 2020	Jun. 30, 2020	Mar. 10, 2020	Apr. 28, 2017
Class of Warrant or Right, Outstanding (in shares)			46,461,630
Stock issued During Period, Value, Exchange of Shares for Warrants		$ 2,470
Preferred Stock Dividends and Other Adjustments, Total			$ 400
Common Stock [Member]
Stock issued During Period, Shares, Exchange of Shares for Warrants (in shares)		2,041,000
Stock issued During Period, Value, Exchange of Shares for Warrants		$ 2
Additional Paid-in Capital [Member]
Stock issued During Period, Value, Exchange of Shares for Warrants		$ 2,468
Exchange Agreement [Member] | Common Stock [Member]
Stock issued During Period, Shares, Exchange of Shares for Warrants (in shares)	2,040,757
Exchange Agreement [Member] | Additional Paid-in Capital [Member]
Stock issued During Period, Value, Exchange of Shares for Warrants	$ 2,500
Series B Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)					0.058
Class of Warrant or Right, Outstanding (in shares)	3,638,780
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.37		$ 13
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			530,381
Series B Warrant [Member] | Exchange Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	0.61
Class of Warrant or Right, Outstanding (in shares)	3,373,900
Series C Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)				1
Class of Warrant or Right, Outstanding (in shares)				25,367,646
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 0.68
Series D Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)				1
Class of Warrant or Right, Outstanding (in shares)				25,367,646
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 0.68

Note 9 - Warrants - Warrants (D

Note 9 - Warrants - Warrants (Details)	6 Months Ended
	Jun. 30, 2020$ / sharesshares
Number of Warrants Outstanding (in shares) | shares	46,461,630
Warrant One [Member]
Exercise Prices (in dollars per share) | $ / shares	$ 0.37
Number of Warrants Outstanding (in shares) | shares	530,381
Range of Expiration Dates	May 2022
Warrant Two [Member]
Exercise Prices (in dollars per share) | $ / shares	$ 0.68
Number of Warrants Outstanding (in shares) | shares	45,823,528
Range of Expiration Dates	March 2021 - March 2025
Warrant Three [Member]
Number of Warrants Outstanding (in shares) | shares	107,721
Range of Expiration Dates	September 2021 - September 2027
Warrant Three [Member] | Minimum [Member]
Exercise Prices (in dollars per share) | $ / shares	$ 13
Warrant Three [Member] | Maximum [Member]
Exercise Prices (in dollars per share) | $ / shares	$ 52.20

Note 10 - Equity Offerings (Det

Note 10 - Equity Offerings (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Jul. 06, 2020	Mar. 10, 2020	Aug. 12, 2019	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Dec. 31, 2019	Apr. 28, 2017
Shares Issued, Price Per Share (in dollars per share)											$ 1
Preferred Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.01			$ 0.01		$ 0.01	$ 0.01
Proceeds from Issuance of Equity Net							$ 13,525	$ 0
Proceeds from Warrant Exercises							$ 3,340	$ 534
Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)					7,030,000
Stock Issued During Period Shares Stock Options and Warrants Exercised (in shares)						25,000	4,900,000		12,000
Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares)				4,884,000	3,053,000		7,900,000
Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)					0
Stock Issued During Period Shares Stock Options and Warrants Exercised (in shares)						0			0
Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares)				(4,884,000)	(3,053,000)		7,900,000
Series C Warrants [Member]
Proceeds from Warrant Exercises							$ 3,300
Series A Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.01
The 2019 Sales Agreement [Member]
Aggregate Number of Shares of Common Stock Available for Sale in Offering (in shares)			25,000,000
Agency Commission as Percentage from Proceeds from Sale Of Common Stock Gross			3.00%
Public Offering [Member]
Proceeds from Issuance of Equity Net		$ 13,500
Public Offering [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues (in shares)	42,857,142
Shares Issued, Price Per Share (in dollars per share)	$ 0.35
Proceeds from Issuance of Equity Net	$ 13,700
Public Offering [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)					14,122,000
Public Offering [Member] | Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)					7,937,000
Public Offering [Member] | Series C Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		3,308,823
Public Offering [Member] | Series D Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		3,308,823
Public Offering [Member] | Class A Units [Member]
Stock Issued During Period, Shares, New Issues (in shares)		14,121,766
Shares Issued, Price Per Share (in dollars per share)		$ 0.68
Public Offering [Member] | Class B Units [Member]
Stock Issued During Period, Shares, New Issues (in shares)		7,937,057
Shares Issued, Price Per Share (in dollars per share)		$ 0.68

Note 10 - Equity Offerings - Su

Note 10 - Equity Offerings - Summary of Sales Under Offering (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Apr. 28, 2017
Average price per share (in dollars per share)			$ 1
Net proceeds	$ 13,525	$ 0
ATM Offering [Member]
Total shares of common stock sold (in shares)	6,687,846
Average price per share (in dollars per share)	$ 1.73
Gross proceeds	$ 11,558
Commissions earned by Cantor	346
Net proceeds	$ 11,212

Note 11 - Restructuring (Detail

Note 11 - Restructuring (Details Textual) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Dec. 31, 2019	Jun. 30, 2020
Restructuring Charges, Total	$ 8,800	$ 858
Restructuring Reserve, Ending Balance	882	988
Accrued Expense [Member]
Restructuring Reserve, Ending Balance		1,000
Inventory Write Down [Member] | Cost of Sales [Member]
Restructuring Charges, Total	7,400
Employee Severance [Member]
Restructuring Charges, Total		$ 900
Employee Severance [Member] | Restructuring and Other Charges [Member]
Restructuring Charges, Total	$ 1,400

Note 11 - Restructuring - Restr

Note 11 - Restructuring - Restructuring Liability (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Dec. 31, 2019	Jun. 30, 2020
Balance		$ 882
Amount charged to operating expenses	$ 8,800	858
Cash payments		(752)
Balance	$ 882	$ 988

Note 12 - Basic and Diluted N_2

Note 12 - Basic and Diluted Net Loss Per Share (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Earnings Per Share, Potentially Dilutive Securities, Warrants (in shares)		100,000		100,000
Fair Value Adjustment of Warrants	$ 114	$ (2,528)	$ 269	$ (2,422)
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)			4,278,967	1,991,111
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)			46,461,630	107,719
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)			3,036,176	476,263

Note 13 - Commitments and Con_2

Note 13 - Commitments and Contingencies (Details Textual) $ in Thousands, € in Millions	Dec. 30, 2016EUR (€)shares	Sep. 21, 2015shares	Jun. 30, 2020USD ($)	Dec. 31, 2019USD ($)
Business Combination, Contingent Consideration, Liability, Total			$ 2,278	$ 1,084
Senhance Surgical Robotic System Acquisition [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | shares	286,360	1,195,647
Business Combination, Contingent Consideration, Liability, Total			$ 2,300	$ 1,100
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | €	€ 5

Note 14 - Subsequent Events (De

Note 14 - Subsequent Events (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Jul. 06, 2020	Mar. 10, 2020	Jun. 30, 2020	Jun. 30, 2019	Jul. 31, 2020	Apr. 28, 2017
Shares Issued, Price Per Share (in dollars per share)						$ 1
Proceeds from Issuance of Equity Net			$ 13,525	$ 0
Series B Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.37			$ 13
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			530,381
Subsequent Event [Member] | Restricted Cash Held with Silicon Valley Bank [Member]
Restricted Cash, Total					$ 500
Subsequent Event [Member] | Silicon Valley Bank [Member]
Letters of Credit Outstanding, Amount					$ 500
Subsequent Event [Member] | Office, Lab and Warehouse Space in Durham, North Carolina [Member]
Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract (Month)					125 months
Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term (Year)					5 years
Lessee, Operating Lease, Liability, to be Paid, Total					$ 5,000
Subsequent Event [Member] | Series B Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.35
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	567,660
Public Offering [Member]
Proceeds from Issuance of Equity Net		$ 13,500
Public Offering [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues (in shares)	42,857,142
Shares Issued, Price Per Share (in dollars per share)	$ 0.35
Proceeds from Issuance of Equity Net	$ 13,700